New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 23, 2014
09:25 EDTSNTI, SNTI, SRNE, SRNE, SPEX, SPEX, CDXC, CDXC, CBMX, CBMX, SSET, SSET, OPK, OPK, CGIX, CGIXRedChip Companies to hold a virtual conference
RedChip Emerging Growth Showcase is being held on January 22-23 with webcasted presentations to begin on January 23 at 9:30 am. Webcast Link
Sign up for a free trial to see the rest of the stories you've been missing.
May 21, 2015
06:35 EDTCDXCChromaDex enters into worldwide license and supply agreement for purple corn
ChromaDex has entered into an exclusive worldwide license and supply agreement for patent-pending Suntava Purple Corn, derived from a proprietary non-GMO purple corn hybrid which contains an extraordinarily high level of anthocyanins. Purple corn is rich in antioxidants and has a natural deep purple color due to the high anthocyanin content. It is grown in the USA. ChromaDex plans to develop an extraction process to concentrate the anthocyanins in Suntava Purple Corn which will be used to produce a highly concentrated anthocyanin ingredient. ChromaDex believes there is a ready market for cost-effective concentrated anthocyanins having application in dietary supplements, sports nutrition, food & beverage and skin care.
May 19, 2015
07:35 EDTSRNEAdvaxis, Sorrento Therapeutics form collaboration
Subscribe for More Information
May 18, 2015
10:03 EDTCDXCChromaDex management to meet with Craig Hallum
Meeting to be held in Minneapolis on May 19 hosted by Craig Hallum.
09:01 EDTSRNESorrento Therapeutics establishes TNK Therapeutics subsidiary
Subscribe for More Information
May 15, 2015
16:17 EDTSRNEOn The Fly: Top stock stories for Friday
Subscribe for More Information
13:01 EDTSRNEOn The Fly: Top stock stories at midday
Subscribe for More Information
12:26 EDTSRNESorrento deal 'huge validation' of potential, says H.C. Wainwright
H.C. Wainwright views NantWorks' acquisition of Sorrento's Cynviloq as "huge validation" of the drug's potential. The firm notes NantWorks is owned by Dr. Patrick Soon-Shiong, who previously launched Abraxane. The firm reiterates a Buy rating on Sorrento with a $20 price target.
10:29 EDTOPKAmerican Urological Association to hold an annual meeting
Subscribe for More Information
09:51 EDTSRNESorrento Therapeutics resumes, up 23% after announcing deal for Cynviloq rights
Subscribe for More Information
09:11 EDTSRNESorrento Therapeutics to resume trading at 9:50 am EDT
Subscribe for More Information
09:07 EDTOPKOPKO Health announces publication of study using kallikrein biomarkers
Subscribe for More Information
09:02 EDTSRNENantWorks acquires rights to Cynviloq
Subscribe for More Information
08:59 EDTSRNESorrento Therapeutics trading halted, pending news
Subscribe for More Information
May 12, 2015
07:36 EDTCGIXCancer Genetics reports Q1 EPS (44c), consensus (54c)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use